Researching and understanding the mechanisms of drug resistance are essential to determine therapies that are more effective on an individual basis. Computational biology tools combined with transcriptome analysis allow the characterization of differential gene expression signatures in response to treatment in resistant vs. non-resistant human-derived cancer cells.
Many biomarkers including noncoding RNAs and alternatively-spliced variants have been associated with tumor pathogenesis or drug resistance. These biomarkers represent candidates to help elucidate the biology of diseases, to identify the mechanisms for drug resistance, and to design better targeted therapies for precision medicine.
In the webinar, Dr. Yesim Gökmen-Polar will describe:
- The importance of alternative splicing and noncoding RNAs in cancer biology
- Transcriptomics workflows using Applied Biosystems Clariom assays to identify biomarkers and drug resistance mechanisms
- Applications in breast and thymic cancer research